Genetic Basis of Positive and Negative Symptom Domains in Schizophrenia

被引:14
作者
Xavier, Rose Mary [1 ]
Vorderstrasse, Allison [2 ]
机构
[1] Duke Univ, Sch Nursing, 307 Trent Dr, Durham, NC 27710 USA
[2] Duke Univ, Sch Nursing, Duke Ctr Appl Genom & Precis Med, Durham, NC 27710 USA
关键词
schizophrenia; genetics; positive symptoms; negative symptoms; METHYLTRANSFERASE VAL158MET POLYMORPHISM; ANTIPSYCHOTIC TREATMENT RESPONSE; BDNF VAL66MET POLYMORPHISM; DOPAMINE TRANSPORTER GENE; A RECEPTOR GENE; CLINICAL SYMPTOMS; 5-HT1A RECEPTOR; INSERTION/DELETION POLYMORPHISM; PSYCHOTIC SYMPTOMS; PREFRONTAL CORTEX;
D O I
10.1177/1099800417715907
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
Schizophrenia is a highly heritable disorder, the genetic etiology of which has been well established. Yet despite significant advances in genetics research, the pathophysiological mechanisms of this disorder largely remain unknown. This gap has been attributed to the complexity of the polygenic disorder, which has a heterogeneous clinical profile. Examining the genetic basis of schizophrenia subphenotypes, such as those based on particular symptoms, is thus a useful strategy for decoding the underlying mechanisms. This review of literature examines the recent advances (from 2011) in genetic exploration of positive and negative symptoms in schizophrenia. We searched electronic databases PubMed, Web of Science, and Cumulative Index to Nursing and Allied Health Literature using key words schizophrenia, symptoms, positive symptoms, negative symptoms, cognition, genetics, genes, genetic predisposition, and genotype in various combinations. We identified 115 articles, which are included in the review. Evidence from these studies, most of which are genetic association studies, identifies shared and unique gene associations for the symptom domains. Genes associated with neurotransmitter systems and neuronal development/maintenance primarily constitute the shared associations. Needed are studies that examine the genetic basis of specific symptoms within the broader domains in addition to functional mechanisms. Such investigations are critical to developing precision treatment and care for individuals afflicted with schizophrenia.
引用
收藏
页码:559 / 575
页数:17
相关论文
共 132 条
  • [1] Adachi Naoki, 2014, World J Biol Chem, V5, P409, DOI 10.4331/wjbc.v5.i4.409
  • [2] Uncovering the Hidden Risk Architecture of the Schizophrenias: Confirmation in Three Independent Genome-Wide Association Studies
    Arnedo, Javier
    Svrakic, Dragan M.
    del Val, Coral
    Romero-Zaliz, Rocio
    Hernandez-Cuervo, Helena
    Fanous, Ayman H.
    Pato, Michele T.
    Pato, Carlos N.
    de Erausquin, Gabriel A.
    Cloninger, C. Robert
    Zwir, Igor
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2015, 172 (02) : 139 - 153
  • [3] Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction
    Ayalew, M.
    Le-Niculescu, H.
    Levey, D. F.
    Jain, N.
    Changala, B.
    Patel, S. D.
    Winiger, E.
    Breier, A.
    Shekhar, A.
    Amdur, R.
    Koller, D.
    Nurnberger, J. I.
    Corvin, A.
    Geyer, M.
    Tsuang, M. T.
    Salomon, D.
    Schork, N. J.
    Fanous, A. H.
    O'Donovan, M. C.
    Niculescu, A. B.
    [J]. MOLECULAR PSYCHIATRY, 2012, 17 (09) : 887 - 905
  • [4] The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders
    Bannon, MJ
    Michelhaugh, SK
    Wang, J
    Sacchetti, P
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 (06) : 449 - 455
  • [5] Do GluA1 knockout mice exhibit behavioral abnormalities relevant to the negative or cognitive symptoms of schizophrenia and schizoaffective disorder?
    Barkus, Chris
    Feyder, Michael
    Graybeal, Carolyn
    Wright, Tara
    Wiedholz, Lisa
    Izquierdo, Alicia
    Kiselycznyk, Carly
    Schmitt, Wolfram
    Sanderson, David J.
    Rawlins, J. Nicholas P.
    Saksida, Lisa M.
    Bussey, Timothy J.
    Sprengel, Rolf
    Bannerman, David
    Holmes, Andrew
    [J]. NEUROPHARMACOLOGY, 2012, 62 (03) : 1263 - 1272
  • [6] Transcription and Pathway Analysis of the Superior Temporal Cortex and Anterior Prefrontal Cortex in Schizophrenia
    Barnes, Michael R.
    Huxley-Jones, Julie
    Maycox, Peter R.
    Lennon, Mark
    Thornber, Amy
    Kelly, Fiona
    Bates, Stewart
    Taylor, Adam
    Reid, Juliet
    Jones, Neil
    Schroeder, Joern
    Scorer, Carol A.
    Davies, Ceri
    Hagan, Jim J.
    Kew, James N. C.
    Angelinetta, Claire
    Akbar, Tariq
    Hirsch, Steven
    Mortimer, Ann M.
    Barnes, Thomas R. E.
    de Belleroche, Jackie
    [J]. JOURNAL OF NEUROSCIENCE RESEARCH, 2011, 89 (08) : 1218 - 1227
  • [7] Bell R, 2000, AM J MED GENET, V96, P736, DOI 10.1002/1096-8628(20001204)96:6<736::AID-AJMG8>3.0.CO
  • [8] 2-2
  • [9] Pharmacogenetic associations of the type-3 metabotropic glutamate receptor (GRM3) gene with working memory and clinical symptom response to antipsychotics in first-episode schizophrenia
    Bishop, Jeffrey R.
    Reilly, James L.
    Harris, Margret S. H.
    Patel, Shitalben R.
    Kittles, Rick
    Badner, Judith A.
    Prasad, Konasale M.
    Nimgaonkar, Vishwajit L.
    Keshavan, Matcheri S.
    Sweeney, John A.
    [J]. PSYCHOPHARMACOLOGY, 2015, 232 (01) : 145 - 154
  • [10] Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia
    Bishop, Jeffrey R.
    Miller, Del D.
    Ellingrod, Vicki L.
    Holman, Timothy
    [J]. HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (01) : 28 - 34